Company and Stock Identity

How Chai Discovery Connects to the Public Market

Company structure
Private company
Market access
No current public listing was verified.
Research focus
The group's question does not apply to this company the usual way, because Chai Discovery has no drug pipeline of its own. The thing to count is what came out of the partnerships. Five pharmaceutical collaborations were announced between June and August 2026, four of them disclosing no financial terms, and none has publicly named a molecule that reached the clinic. Ask each partner, not Chai, what the model actually produced.

Chai Discovery announced a 400 million dollar Series C on 14 July 2026 at a stated valuation of 3.8 billion dollars, led by Index Ventures and Kleiner Perkins alongside Sequoia Capital, Dimension and others. No change of control was announced. Checked on 2026-10-10.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Chai Discovery ... Company source

GSK takes Chai Discovery's designs into its own labs first, then signs a collaboration

Chai Discovery announced on 9 October 2026 that GSK will get access to its platform, including its protein folding and design models, to support discovery work across GSK's pipeline. The announcement says the deal followed a wet-lab evaluation in which Chai's models generated designs against GSK targets zero-shot, without training on those targets, and that GSK then tested the designs itself. Chai's wording is that GSK conducted internal wet-lab testing of the designs, finding binders to all tested targets. Christopher Austin, GSK's senior vice president of R&D technologies, is quoted saying GSK evaluated the models across a panel of diverse targets and saw designs with strong binding affinities. Joshua Meier, Chai's co-founder and chief executive, is quoted saying the evaluation let both teams assess the models against a range of therapeutic targets in the lab. No payments, milestones or number of programs were disclosed.

Why it matters: A binder is a long way from a medicine. It means a designed molecule stuck to the thing it was aimed at, which is the first hurdle of many, and nothing here says any of it will help a patient. What makes this one worth noting is who ran the test. The lab work was done inside GSK on GSK's own targets, so the result is not the AI company grading its own homework. Zero-shot matters for the same reason: the models had not been tuned on those particular targets, which is closer to how a new program actually starts. The open question is money. No payments or program counts were disclosed, so this could be a broad licence or a small pilot, and the announcement does not say which.

... Chai Discovery ... Company source

Bristol Myers Squibb will use Chai Discovery's AI models to design antibodies

Chai Discovery said on 20 August 2026 that it is collaborating with Bristol Myers Squibb on AI-driven therapeutic antibody discovery. The company says Bristol Myers Squibb will use its AI models and platform, including its molecular folding and design models, to support antibody candidate discovery across its portfolio, and describes its technology as predicting and reprogramming molecular interactions so scientists can design biomolecules with specific properties. No financial terms are disclosed in the announcement.

Why it matters: A collaboration with no disclosed money is usually an evaluation rather than a commitment, and that is worth knowing before reading it as validation. What it does show is that a large developer was willing to put its name on the work, which in antibody discovery is not free. The useful measure a year from now will be whether any of these five partners takes a Chai-designed antibody into development, because a tool that gets used but produces nothing filed is a line item, not a platform.

... Chai Discovery ... Company source

argenx gets early access to Chai Discovery's antibody design platform

Chai Discovery said on 15 July 2026 that it entered a collaboration agreement with argenx, giving argenx early access to its platform for designing antibodies from scratch against therapeutic targets. The company describes Chai-2 as the first zero-shot antibody design platform to reach double-digit experimental hit rates, and says its newer Chai-3 model improves on therapeutic binding, hard-to-drug targets, multispecific design, developability and generalisation. No financial terms are stated.

Why it matters: A double-digit hit rate for designing an antibody with no prior examples would be a genuine change, because traditional discovery screens enormous libraries to find a few that bind. The figure is the company's own and the word to watch is experimental: it means something was made and tested, which is a higher bar than a computational score, but it is still Chai's own bench rather than an independent one. argenx is an antibody company with its own strong discovery engine, so it choosing to evaluate this is a more informative signal than a general technology partnership.

... Chai Discovery ... Company source

Chai Discovery raises 400 million dollars at a 3.8 billion dollar valuation

Chai Discovery said on 14 July 2026 that it raised 400 million dollars at a stated valuation of 3.8 billion dollars, in a round led by Index Ventures and Kleiner Perkins alongside Sequoia Capital, Dimension and other investors. The company says the money will expand the compute, data and research behind its models, speed up product development and put the technology in front of more scientists, and that its latest model, Chai-3, is being adopted across Eli Lilly, Pfizer and Novartis.

Why it matters: Spending a round this size on compute and data rather than on a laboratory is the clearest statement of what Chai Discovery is: a model company selling to drug companies, not a drug company. For a research team that is good news on access and bad news on alignment, because the vendor's incentive is adoption across many partners rather than one programme succeeding. A 3.8 billion dollar valuation on no approved product also means the next round depends on partners renewing, so ask about contract length before building a workflow on it.

... Chai Discovery ... Company source

Novartis gets access to Chai Discovery's antibody design models

Chai Discovery announced on 13 July 2026 that Novartis will get access to its AI models, including Chai-3, to support therapeutic antibody discovery across multiple targets. Financial terms were not disclosed, and the announcement gives no number of programs or milestones. Fiona Marshall, Novartis's president of biomedical research, is quoted saying AI is already reshaping how the company discovers medicines and that applying advanced models to problems like antibody design lets it explore a broader range. Joshua Meier, Chai's co-founder and chief executive, is quoted calling it a significant step forward. The announcement also names Pfizer and Eli Lilly as earlier users of Chai's models.

Why it matters: This is an access agreement, which is the lightest kind of deal in this field. A large drug company can hand a model to a research group, try it on a few targets and walk away without ever announcing that it stopped. Nothing here is a result, and nothing here involves a patient. What it does tell a biologics team is that the design models cleared whatever internal review Novartis runs before outside software touches real programs, and that Chai now has three of the largest drug companies on that list. Treat the names as a signal about the software being taken seriously, not as evidence that it works.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: The careers page listed 16 roles across science, research engineering, platform and product, partnerships and operations, including antibody engineering, protein design, machine learning infrastructure and forward-deployed scientist positions. The company says the work is in person in San Francisco.

Qualification signal: The useful background here sits across two fields at once, because the models are judged by whether a designed antibody works at the bench. Wet-lab antibody engineering experience beside machine learning is the combination the job list keeps asking for, and a forward-deployed scientist role means talking to pharmaceutical scientists is part of the job.

Check current roles at Chai Discovery. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Pharmaceutical R&D, biotechnology leadership, translational science, business development, and investors
Primary use case
Identify targets, design molecules, prioritize experiments, and connect biomedical data to research decisions
Typical deployment
Ranges from software and data partnerships to platform collaborations and internally owned drug pipelines

Evidence questions

  • Which results are prospective, reproduced, and tied to a clinical or experimental endpoint?
  • How many programs are AI-originated, AI-assisted, partnered, or internally owned?
  • What has advanced beyond target identification and preclinical reporting?

Regulatory and workflow questions

  • Which entity owns development, validation, and regulatory responsibility for each program?
  • How are model-generated hypotheses reviewed before experimental or clinical use?
  • What claims are about research productivity versus a regulated product?

Data and contract questions

  • Who owns generated molecules, targets, models, and derived data?
  • Which proprietary datasets create defensibility and which are licensed?
  • Can a partner reproduce outputs and export project data after the collaboration?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

First-Hand Sources